Abstract P330: Effect of Randomized Omega-3 Treatment on Downstream Bioactive Lipids and Their Association With Incident Cardiovascular Disease Events: Metabolomic Studies of the Vital and Jupiter Trials

• Published in: Circulation (New York, N.Y.) N.Y.), 2023-02, Vol.147 (Suppl_1), p.AP330-AP330
• Main Authors: Demler, Olga, Liu, Yanyan, Alotaibi, Mona, Hoshi, Rosangela, Giulianini, Franco, Gibson, Heike, Watrous, Jeramie, Cook, Nancy R, Costenbader, Karen, Okereke, Olivia, Glynn, Robert, Ridker, Paul M, Manson, Joann E, Cheng, Susan, Chasman, Daniel, Jain, Mohit, Mora, Samia
• Format: Article
• Language: English
• ISSN: 0009-7322; 1524-4539
• DOI: 10.1161/circ.147.suppl_1.P330

BackgroundThe effect of omega-3 (n-3) treatment on cardiovascular disease (CVD) outcomes in randomized controlled trials remains inconsistent. We hypothesize that the downstream products of n-3 metabolism, including bioactive lipids (BALs), have a heterogeneous relationship with CVD, which may provide insight into response heterogeneity. MethodsUsing state of the art LC-MS, we assayed the plasma bioactive lipidome (>10K BALs) across 3,512 individuals at baseline and Y1 or -2, in the VITAL substudies (CVD case control N=1540; CTSC subcohort N=1054; 45% women, median age 70, 20% non-white) and JUPITER CVD case control (N=918) (NCT01169259, NCT00239681). Linear regression revealed BALs that change consistently with n-3 treatment (n3BALs) (discovery in VITAL controls, validation in an independent VITAL CTSC substudy, cumulative FDR .05). n3BALs that are also associated with CVD in VITAL CVD were identified using adjusted conditional logistic regression (p